Cidara Therapeutics, Inc. 20D.F Stock
Cidara Therapeutics, Inc. Price Chart
Cidara Therapeutics, Inc. 20D.F Financial and Trading Overview
| Cidara Therapeutics, Inc. stock price | 0.77 EUR |
| Previous Close | 1.07 EUR |
| Open | 1.02 EUR |
| Bid | 1.02 EUR x 40000 |
| Ask | 1.05 EUR x 40000 |
| Day's Range | 1.02 - 1.02 EUR |
| 52 Week Range | 0.42 - 2.02 EUR |
| Volume | 500 EUR |
| Avg. Volume | 1.94K EUR |
| Market Cap | 91.59M EUR |
| Beta (5Y Monthly) | 1.295422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.04 EUR |
20D.F Valuation Measures
| Enterprise Value | 48.99M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.7205674 |
| PEG Ratio (5 yr expected) | -0.04 |
| Price/Sales (ttm) | 1.1012573 |
| Price/Book (mrq) | 3.409396 |
| Enterprise Value/Revenue | 0.589 |
| Enterprise Value/EBITDA | -5.872 |
Trading Information
Cidara Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.295422 |
| 52-Week Change | 130.76% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.02 EUR |
| 52 Week Low | 0.42 EUR |
| 50-Day Moving Average | 1.06 EUR |
| 200-Day Moving Average | 0.93 EUR |
20D.F Share Statistics
| Avg. Volume (3 month) | 1.94K EUR |
| Avg. Daily Volume (10-Days) | 200 EUR |
| Shares Outstanding | 90.03M |
| Float | 70.28M |
| Short Ratio | N/A |
| % Held by Insiders | 9.46% |
| % Held by Institutions | 32.24% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -9.99% |
| Operating Margin (ttm) | -10.19% |
| Gross Margin | 10.94% |
| EBITDA Margin | -10.032% |
Management Effectiveness
| Return on Assets (ttm) | -7.73% |
| Return on Equity (ttm) | -52.26% |
Income Statement
| Revenue (ttm) | 83.17M EUR |
| Revenue Per Share (ttm) | 1.15 EUR |
| Quarterly Revenue Growth (yoy) | 265.60% |
| Gross Profit (ttm) | -11232000 EUR |
| EBITDA | -8344000 EUR |
| Net Income Avi to Common (ttm) | -8986000 EUR |
| Diluted EPS (ttm) | -0.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 47.98M EUR |
| Total Cash Per Share (mrq) | 0.53 EUR |
| Total Debt (mrq) | 1M EUR |
| Total Debt/Equity (mrq) | 3.73 EUR |
| Current Ratio (mrq) | 2.229 |
| Book Value Per Share (mrq) | 0.298 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15763000 EUR |
| Levered Free Cash Flow (ttm) | -11463000 EUR |
Profile of Cidara Therapeutics, Inc.
| Country | Germany |
| State | CA |
| City | San Diego |
| Address | 6310 Nancy Ridge Drive |
| ZIP | 92121 |
| Phone | 858 752 6170 |
| Website | https://www.cidara.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 73 |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Q&A For Cidara Therapeutics, Inc. Stock
What is a current 20D.F stock price?
Cidara Therapeutics, Inc. 20D.F stock price today per share is 0.77 EUR.
How to purchase Cidara Therapeutics, Inc. stock?
You can buy 20D.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cidara Therapeutics, Inc.?
The stock symbol or ticker of Cidara Therapeutics, Inc. is 20D.F.
Which industry does the Cidara Therapeutics, Inc. company belong to?
The Cidara Therapeutics, Inc. industry is Biotechnology.
How many shares does Cidara Therapeutics, Inc. have in circulation?
The max supply of Cidara Therapeutics, Inc. shares is 90.62M.
What is Cidara Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Cidara Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Cidara Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Cidara Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Cidara Therapeutics, Inc. company belong to?
The Cidara Therapeutics, Inc. sector is Healthcare.